Clinilabs and Ambulatory Monitoring. Inc., Form Strategic Alliance
Clinilabs has entered into a strategic alliance withAmbulatory Monitoring, Inc. (AMI), a medical device and service company.
AMI, located in Ardsley, NY, provides equipment for monitoring physiological functioning in ambulatory subjects. The company’s series of Motionlogger® Actigraphs are commercial devices for 24-hour monitoring of activity and sleep and have been validated through use in hundreds of studies in numerous clinical populations. AMI’s activity monitors can be applied in clinical trials of therapeutics for sleep, psychiatric, pain, hyperactivity, dermatologic (e.g., itch), and cardiovascular disorders, among others. AMI also providesthe original PVT-192 Psychomotor Vigilance Task Monitor.
The alliance brings together AMI’s instrumentation with Clinilabs’ core laboratory. Clinilabs’ core laboratory aggregates and processes electrocardiographic (ECG), polysomnographic (PSG), electroencephalographic (EEG), and electromyographic (EMG) data for clinical studies, offering pharmaceutical companies centralized services that standardize data obtained in multicenter trials. Centralized actigraphy has been offered jointly by Clinilabs and AMI since 2005.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.
